Federated Hermes, Inc. Arcellx, Inc. Transaction History
Federated Hermes, Inc.
- $43.9 Billion
- Q1 2025
A detailed history of Federated Hermes, Inc. transactions in Arcellx, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 46,224 shares of ACLX stock, worth $3.01 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
46,224
Previous 156,094
70.39%
Holding current value
$3.01 Million
Previous $11.9 Million
74.5%
% of portfolio
0.01%
Previous 0.03%
Shares
10 transactions
Others Institutions Holding ACLX
# of Institutions
214Shares Held
48.8MCall Options Held
764KPut Options Held
296K-
Paradigm Biocapital Advisors LP New York, NY4.49MShares$293 Million15.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.99MShares$260 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$244 Million23.3% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$229 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$198 Million4.14% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.85B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...